SPOTLIGHT -
Opdivo, Opdualag Still Benefits Patients With Melanoma at 2 Years
After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.
Three-Drug Regimen Is Promising Across Kidney Cancer Subtypes
Cabometyx, Opdivo and Yervoy led to high disease control rates across different subgroups of patients with kidney cancer, research showed.
Erleada Has ‘Robust Real-World Effectiveness’ in Prostate Cancer
Erleada showed promising results in patients with metastatic castration-sensitive prostate cancer when compared with Xtandi and Zytiga.
Patients With Myeloma Must Recognize the Signs of Cytokine Release Syndrome
Patients with myeloma who are being treated with Tecvayli must discuss symptoms of cytokine release syndrome with their providers as soon as they happen.
